OncoSil Medical Limited

Equities

OSL

AU000000OSL3

Pharmaceuticals

Market Closed - Australian S.E. 02:10:53 2024-07-15 am EDT 5-day change 1st Jan Change
0.008 AUD +14.29% Intraday chart for OncoSil Medical Limited +33.33% -11.11%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
OncoSil Medical Treats Fifth Pancreatic Cancer Patient with Proprietary Device MT
Oncosil Medical Treats 200th Pancreatic Cancer Patient with Proprietary Device MT
Oncosil Medical Enters Distribution Agreement with Abdulla Fouad Group for Saudi Arabia MT
OncoSil Medical Raises AU$5.3 Million under Entitlement Offer MT
OncoSil Medical Treats Two More Patients in Netherlands in Pancreatic Cancer Trial MT
OncoSil Medical Treats First Commercial Patient in Turkey with Implantable Pancreatic Cancer Device MT
OncoSil Medical Treats First UK Patient for Pancreatic Cancer Study MT
OncoSil Medical Obtains Device Reimbursement Approval in UK MT
First Austria-Based Patients Treated Using OncoSil Pancreatic Cancer Device MT
Oncosil Medical Issues Non-Renounceable Entitlement Offer Prospectus MT
Oncosil Medical to Raise Over AU$7 Million via Placement, Entitlement Offer MT
OncoSil Medical Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Australian Shares End Eight-Day Winning Streak as Early US Fed Rate Cut Hopes Fade MT
OncoSil Device Included in German Funding Program Negotiations; Shares Jump 14% MT
OncoSil Strikes Exclusive Distribution Deal For Turkish Market; Shares Jump 14% MT
OncoSil Medical Receives AU$1.1 Million R&D Tax Rebate MT
First Patient Treated in OncoSil Medical's Pancreatic Cancer Drug Trial MT
Oncosil Medical Limited Elects Gabrielle Liberatore as Director CI
Australian Shares Rise on Expectations of Easing October CPI MT
OncoSil Medical Secures Insurer Clearance for Pancreatic Cancer Device in Israel MT
OncoSil Medical Limited Announces Retirement of Brian Leedman from the Board CI
OncoSil Medical Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Oncosil Medical Limited Announces Change of Principal Place of Business CI
OncoSil Medical Limited Appoints Doug Cubbin as Director CI
Oncosil Medical Appoints Incoming Chair MT
Chart OncoSil Medical Limited
More charts
OncoSil Medical Ltd is an Australia-based medical device company focused on localized treatments for patients with unresectable locally advanced pancreatic cancer (LAPC). The Company is focused on the development and commercialization of its lead product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The Company has developed a cancer treatment device, the OncoSil brachytherapy device, which is a critical component of a brachytherapy treatment for locally advanced unresectable pancreatic cancer. The OncoSil device delivers a targeted intratumoral placement of Phosphorous-32 (32P) in the treatment of locally advanced unresectable pancreatic cancer. The OncoSil device has received a device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. OSL Stock
  4. News OncoSil Medical Limited
  5. Oncosil Medical Treats 200th Pancreatic Cancer Patient with Proprietary Device